A conditional multi-signal validation framework for cancer immunotherapy: the adaptive anti-error biological system

Area of Science:

• Immunology
• Computational Biology
• Oncology

Background:

• Current cancer immunotherapies are limited by single-signal approaches, leading to antigen loss, off-tumor toxicity, and tumor heterogeneity.
• Therapeutic failure often stems from biological decision errors: false-positive activation in normal tissues and missed recognition in antigen-low tumors.

Purpose of the Study:

• Propose the Adaptive Anti-Error Biological System (AABS) as a conceptual framework to enhance therapeutic precision.
• Introduce AABS-01, a simplified trimodular model integrating tumor priming, dual-signal AND-gate logic, and conditional effector activation.

Main Methods:

• AABS-01 utilizes three layers: Tumor Priming (IFN-γ conditioning, epigenetic modulation, TME normalization), Validation (AND-gate logic for dual tumor-associated signals), and Effector (conditional immune activation).
• Bioinformatic analysis of TCGA and GTEx v8 transcriptomic data to identify and validate candidate signal pairs.

Main Results:

• Four candidate signal pairs (e.g., HER2/MUC4, EGFR/EpCAM) showed corrected Tumor Specificity Index (TSI) values from 18.3x to 46.8x across six cancer types.
• AND-gate logic demonstrated a 3-8x reduction in false-positive rates compared to single-signal methods under observed signal co-regulation.

Conclusions:

• AABS represents a paradigm shift towards decision-based cancer immunotherapy, moving beyond reactive strategies.
• The framework is grounded in T-cell multi-signal activation and kinetic proofreading principles, with a roadmap for validation.